Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment
出版年份 2017 全文链接
标题
Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment
作者
关键词
-
出版物
Blood Cancer Journal
Volume 7, Issue 5, Pages e565
出版商
Springer Nature
发表日期
2017-05-26
DOI
10.1038/bcj.2017.40
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Preclinical models of Waldenström's macroglobulinemia and drug resistance
- (2016) Sikander Ailawadhi et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Novel therapeutic targets in Waldenstrom macroglobulinemia
- (2016) Aneel Paulus et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Postibrutinib outcomes in patients with mantle cell lymphoma
- (2016) P. Martin et al. BLOOD
- Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
- (2016) Andrew W. Roberts et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells
- (2016) A Paulus et al. Blood Cancer Journal
- Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
- (2015) P. Jain et al. BLOOD
- Mechanisms of ibrutinib resistance in chronic lymphocytic leukaemia and non-Hodgkin lymphoma
- (2015) Shuang Q. Zhang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells
- (2015) Kasyapa Chitta et al. BRITISH JOURNAL OF HAEMATOLOGY
- The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity inCXCR4Wild-typeandCXCR4WHIMmutated Waldenstrom macroglobulinaemia cells
- (2015) Yang Cao et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia
- (2015) F. Cervantes-Gomez et al. CLINICAL CANCER RESEARCH
- Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial
- (2015) Ariel Lopez-Chavez et al. JOURNAL OF CLINICAL ONCOLOGY
- MYD88 Mutations and Response to Ibrutinib in Waldenström's Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia
- (2015) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
- (2015) D C Phillips et al. Blood Cancer Journal
- Waldenstrom macroglobulinemia: prognosis and management
- (2015) A Oza et al. Blood Cancer Journal
- Immunophenotyping of Waldenströms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications
- (2015) Aneel Paulus et al. PLoS One
- Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
- (2014) S. P. Treon et al. BLOOD
- Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways
- (2014) Xiaoxian Zhao et al. BRITISH JOURNAL OF HAEMATOLOGY
- CXCR4WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplantMYD88L265P-directed survival signalling in Waldenström macroglobulinaemia cells
- (2014) Yang Cao et al. BRITISH JOURNAL OF HAEMATOLOGY
- Ibrutinib Treatment of CLL: The Cancer Fights Back
- (2014) Ryan M. Young et al. CANCER CELL
- Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers
- (2014) T. A. Yap et al. CLINICAL CANCER RESEARCH
- The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom’s Macroglobulinemia
- (2014) Y Cao et al. LEUKEMIA
- Functional characterization of BTK C481S mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors
- (2014) S Cheng et al. LEUKEMIA
- Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
- (2014) Jennifer A. Woyach et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ibrutinib Resistance in Chronic Lymphocytic Leukemia
- (2014) Richard R. Furman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
- (2014) S M Ansell et al. Blood Cancer Journal
- Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia
- (2014) K Chitta et al. Blood Cancer Journal
- Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
- (2014) D. Chiron et al. Cancer Discovery
- The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
- (2013) Z. R. Hunter et al. BLOOD
- AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia
- (2013) Aneel Paulus et al. BRITISH JOURNAL OF HAEMATOLOGY
- Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells
- (2013) Kasyapa S. Chitta et al. LEUKEMIA & LYMPHOMA
- ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
- (2013) Andrew J Souers et al. NATURE MEDICINE
- “Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia’’
- (2013) P Oppezzo et al. Blood Cancer Journal
- Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner
- (2011) Aisha Masood et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia
- (2011) Pooja P Advani et al. Expert Opinion on Drug Metabolism & Toxicology
- Coordination of mitochondrial bioenergetics with G1phase cell cycle progression
- (2010) Stefan M. Schieke et al. CELL CYCLE
- Targeting the Bcl-2
- (2010) Mehul P Patel et al. CURRENT OPINION IN ONCOLOGY
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma
- (2009) Asher A. Chanan-Khan et al. LEUKEMIA & LYMPHOMA
- Direct multiplexed measurement of gene expression with color-coded probe pairs
- (2008) Gary K Geiss et al. NATURE BIOTECHNOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started